Clinical Trials | July 10, 2025
82% of people prefer diagnostic centers over hospitals for preventive checkups in India
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
The company showcased three core programs developed through this platform
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
A triple-action Formula for comprehensive respiratory relief
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Subscribe To Our Newsletter & Stay Updated
